468 related articles for article (PubMed ID: 22309663)
41. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.
Leroux-Roels G
Expert Opin Biol Ther; 2009 Aug; 9(8):1057-71. PubMed ID: 19555313
[TBL] [Abstract][Full Text] [Related]
42. GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.
Jones T
Curr Opin Mol Ther; 2009 Jun; 11(3):337-45. PubMed ID: 19479667
[TBL] [Abstract][Full Text] [Related]
43. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
van der Velden MV; Aichinger G; Pöllabauer EM; Löw-Baselli A; Fritsch S; Benamara K; Kistner O; Müller M; Zeitlinger M; Kollaritsch H; Vesikari T; Ehrlich HJ; Barrett PN
Vaccine; 2012 Sep; 30(43):6127-35. PubMed ID: 22884662
[TBL] [Abstract][Full Text] [Related]
44. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
45. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.
Hasegawa H; Ichinohe T; Tamura S; Kurata T
Expert Rev Vaccines; 2007 Apr; 6(2):193-201. PubMed ID: 17408369
[TBL] [Abstract][Full Text] [Related]
46. Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.
Gillard P; Chu DW; Hwang SJ; Yang PC; Thongcharoen P; Lim FS; Dramé M; Walravens K; Roman F
BMC Infect Dis; 2014 Mar; 14():142. PubMed ID: 24628789
[TBL] [Abstract][Full Text] [Related]
47. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
[TBL] [Abstract][Full Text] [Related]
48. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly.
Fragapane E; Gasparini R; Schioppa F; Laghi-Pasini F; Montomoli E; Banzhoff A
Clin Vaccine Immunol; 2010 Nov; 17(11):1817-9. PubMed ID: 20810680
[TBL] [Abstract][Full Text] [Related]
49. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.
Ehrlich HJ; Müller M; Oh HM; Tambyah PA; Joukhadar C; Montomoli E; Fisher D; Berezuk G; Fritsch S; Löw-Baselli A; Vartian N; Bobrovsky R; Pavlova BG; Pöllabauer EM; Kistner O; Barrett PN;
N Engl J Med; 2008 Jun; 358(24):2573-84. PubMed ID: 18550874
[TBL] [Abstract][Full Text] [Related]
50. MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.
Puig Barberà J; González Vidal D
Expert Rev Vaccines; 2007 Oct; 6(5):659-65. PubMed ID: 17931147
[TBL] [Abstract][Full Text] [Related]
51. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus.
Carter NJ; Plosker GL
BioDrugs; 2008; 22(5):279-92. PubMed ID: 18778110
[TBL] [Abstract][Full Text] [Related]
52. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
53. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects.
Gasparini R; Schioppa F; Lattanzi M; Barone M; Casula D; Pellegrini M; Veitch K; Gaitatzis N
Int J Clin Pract; 2010 Mar; 64(4):432-8. PubMed ID: 20039974
[TBL] [Abstract][Full Text] [Related]
54. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis.
Banzhoff A; Pellegrini M; Del Giudice G; Fragapane E; Groth N; Podda A
Influenza Other Respir Viruses; 2008 Nov; 2(6):243-9. PubMed ID: 19453401
[TBL] [Abstract][Full Text] [Related]
55. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells.
Bencharitiwong R; Leonard S; Tsai T; Nowak-Węgrzyn A
Hum Vaccin Immunother; 2012 Jul; 8(7):863-5. PubMed ID: 22777093
[TBL] [Abstract][Full Text] [Related]
56. Development of vaccines against influenza A virus (H5N1).
Li WC; Huang YC
Chang Gung Med J; 2007; 30(4):294-304. PubMed ID: 17939259
[TBL] [Abstract][Full Text] [Related]
57. Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children.
Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Sawata H; Nakura N; Jaeger RK; Lattanzi M
Adv Ther; 2010 Jul; 27(7):444-57. PubMed ID: 20586002
[TBL] [Abstract][Full Text] [Related]
58. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.
Banzhoff A; Haertel S; Praus M
Hum Vaccin; 2011 May; 7(5):539-48. PubMed ID: 21422814
[TBL] [Abstract][Full Text] [Related]
59. A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two.
Moro ML; Nobilio L; Voci C; Di Mario S; Candela S; Magrini N;
Vaccine; 2013 Feb; 31(10):1438-46. PubMed ID: 22885015
[TBL] [Abstract][Full Text] [Related]
60. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults.
Banzhoff A; Gasparini R; Laghi-Pasini F; Staniscia T; Durando P; Montomoli E; Capecchi PL; di Giovanni P; Sticchi L; Gentile C; Hilbert A; Brauer V; Tilman S; Podda A
PLoS One; 2009; 4(2):e4384. PubMed ID: 19197383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
